William Blair analyst Andy Hsieh downgrades Actinium Pharmaceuticals (AMEX:ATNM) from Outperform to Market Perform.
CalAmp Q2 EPS $(0.02) Beats $(0.03) Estimate, Sales $72.80M Beat $69.27M Estimate
CalAmp (NASDAQ:CAMP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. This is a 125 percent decrease over earnings of $0.08 per share from the same
